The 2024 American Diabetes Association (ADA) guidelines introduce pivotal updates in managing type 2 diabetes (T2D). These updates focus on enhancing cardiovascular health, managing obesity and leveraging advanced technology in diabetes care. Key highlights include strategies for incorporating new anti-obesity medications into treatment plans, enhanced screening for cardiovascular complications such as heart failure and peripheral arterial disease and integration of continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems into care. Additional guidance emphasizes the use of telehealth and digital tools to improve diabetes self-management education and outcomes.
The guidelines stress the importance of personalized care, with a focus on minimizing complications and improving quality of life. Special attention is given to weight management and addressing comorbidities such as hypoglycemia and non-alcoholic fatty liver disease (NAFLD), both of which are prevalent in people with diabetes.
On the treatment side, some recommendations include:
- In people with type 2 diabetes and established ASCVD, multiple ASCVD risk factors, or diabetic kidney disease (DKD), an SGLT2 inhibitor with demonstrated CV benefit is recommended to reduce the risk of MACE and/or HF hospitalization.
- In people with type 2 diabetes and established HF with either preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), an SGLT2 inhibitor with proven benefit in this patient population is recommended to reduce risk of worsening HF and CV death.
How can CGMs and AID systems be seamlessly integrated into routine care to enhance patient outcomes in T2D management? How can new drug classes like SGLT2i help?
Share
-
BELINDA VELAZQUEZMarch 30, 2025CGM had helped patients for tighter control of globose specially on pts that are afraid of doing accuchecks at home Also SGLt2 are great drugs for prevention of cardiovascular disease -
N JainMarch 30, 2025This will significantly enhance patient outcomes by providing more precise glucose control and minimizing complications.